OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Shah, K., Praet, C., Devlin, N., Sussex, J., Appleby, J. and Parkin, D.

Research Paper
May 2011

The appraisal of health care technologies by the UK’s National Institute for Health and Clinical Excellent (NICE) focuses on cost effectiveness, usually measured in terms of incremental cost per quality adjusted life year (QALY) gained.  According to the findings presented in this Research Paper, however, cost effectiveness does not appear to be the dominant consideration in NHS decisions about resource allocation.

Devlin, N. and Sussex, J.

Monograph
March 2011

What a health care system should pay for depends, of course, on the health gain that results.  Health technology assessment (HTA) and cost-effectiveness analysis have become the core for many such decisions, by NICE in the UK and by similar bodies elsewhere.  Other factors, however, also are taken into account by the governments and insurers who fund health care.  These typically include: the impact of decisions on social equity; the quality of the patient experience; ramifications for the wider economy; and the quality of evidence required for decision

O'Neill, P.

Monograph
November 2010

In December 2006, the National Institute for Health and Clinical Excellence (NICE) issued guidance for preventing and managing overweight and obesit. Recommendations are step-wise, starting with lifestyle changes and progressing through medicine to bariatric surgery. The guidance recommends that patients considered for bariatric surgery have either a BMI of 40 or more, or a BMI over 35 with an associated condition such as diabetes. Costing guidelines are included in the guidance.

Sussex, J., Shah, K. and Butler, J.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.

Sussex, J. and Shah, K.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.

Garau, M., Shah, K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F.

Research Paper
October 2010

Current methods for constructing quality adjusted life year (QALY) measurements may be deficient for cancer patients in three respects: descriptions of health state, valuation of health state, and the source of values upon which measures are based.

Existing measures of health are either not sensitive enough or not attuned to cancer patients’ actual preferences.  For example, evidence suggests that the EQ 5D instrument does not capture the small changes in health that often are very important to cancer patients.

Culyer, A.

Briefing
June 2009

In the UK and elsewhere, choices about how to allocate health care resources are guided not only by economic calculations, but also by social value judgments such as those relating to equity and fairness. Factors such as uncertainty around key values, operational feasibility and stakeholder interests also need to be considered. The question of how to combine these inputs is central to the field of health care decision making.

Garau, M., Shah, K., Towse, A., Wang, Q., Drummond, M.F. and Mason, A. R.

Consulting Report
February 2009

Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor in lower use in the UK. This Report is based on both a detailed literature review and interviews with key experts directly involved in the work of UK HTA bodies.

Health Economics Research Group, Office of Health Economics and RAND Europe.

Consulting Report
November 2008

Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study. This report is the outcome of a one-year study commissioned by the UK Academy of Medical Sciences, the UK Medical Research Council and the Wellcome Trust. Its purpose is to compare the economic benefits accruing in the UK from medical research funded in the UK, publicly or by charities only, to the cost of that research.

Drummond, M.F. and Rutten, F.

Briefing
November 2008

Australia was the first, in 1993, to make economic evaluation an important component of its decisions about reimbursement of drugs.  Since then, several jurisdictions have followed suit.  Decision-making authorities (e.g., ministries of health or health technology assessment agencies) usually issue methodological guidelines for the conduct of studies of economic value.  Similarities across countries in the sets of guidelines likely are greater than the differences, especially among those guidelines that have been developed in the context of formal decision-making procedures.

Pages